Phase I trial of ZEN003694 (ZEN-3694) in combination with capecitabine in patients with solid tumors
Study of ZEN003694 (ZEN-3694) in Combination with Capecitabine in Patients with Solid Tumors
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAU8602
U.S. Govt. ID: NCT05803382
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the safety of a drug called ZEN003694 (ZEN-3694), in combination with the usual approach of capecitabine. This study tests different doses of ZEN003694 in combination with capecitabine to see which dose is safer for people. There will be between 21 and 30 people taking part in this study. This drug combination is not approved by the FDA for treatment of the disease being studied. Cancers include: colon and rectal cancer, liver cancer, pancreatic cancer, and stomach cancer.
Investigator
Ryan Moy, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with one of the cancers listed? Yes No
Are you willing to make regularly scheduled visits to the clinic for treatment and evaluation? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE